The Third Henry
Stewart One-Day Briefing on
Latest Thinking
on
Attacking/Defending Patent Rights in the
U.S. Pharmaceutical Market
“This
briefing is about ensuring you are completely up to date on the latest
developments in offensive and defensive strategies, tactics and practice.”
David B. Clissold, Hyman, Phelps & McNamara P.C.
This
is a leading edge briefing on the law and practice of defending and
avoiding exclusive United States marketing rights in the pharmaceutical
industry. It will consider HOW THE LAW STANDS NOW, HOW IT HAS BEEN
INTERPRETED BY THE FDA, PTO, FTC AND THE COURTS, and HOW IT IS LIKELY
TO BE INTERPRETED IN THE FUTURE. It will also suggest how companies
should adapt in order to protect their legal rights and expand their
economic opportunities.
Delivered
by some of the subject’s leading experts the briefing covers:
-
The Hatch-Waxman Act – current rules, the new legislative and regulatory changes, and how companies should adapt
-
Maximizing and defending patents – strategies for patent and NDA holders
-
Challenging patents – strategies and tactics for generic challengers
-
The trends in court decisions and implications for patent protected companies and generic manufacturers
-
FDA and PTO policies and rules: factoring them into your decisions
-
Strategies under the new Orange Book rules (August 2003)
-
How the Federal Trade Commission’s activities affect decision making
-
How the Attorneys General are responding to unwarranted patent extensions and curtailing improper patent manipulation
-
Understanding the trend of class action lawsuits challenging exclusive marketing arrangements
“The
questions remain the same – it’s the answers that have moved
on.”
Thomas M. Saunders, Brown Rudnick Berlack Israels LLP
For everyone seeking
to defend or challenge pharmaceutical patents – principals and
lawyers alike.
Full documentation will be provided to all delegates and adequate
time set aside for questions.
Wednesday,
8 December 2004
Jury’s Washington Hotel, Washington DC